The US Food and Drug Administration (FDA) has allowed Moderna, an American biotechnology company, founded by renowned businessman Noubar Afeyan, to proceed to the second phase of the research on the coronavirus vaccine.

The second state of research, according to the company, will begin quite soon, and the third phase is scheduled for early summer.

The mRNA-1273 experimental vaccine was developed 42 days after Chinese scientists deciphered and published the genetic code of the virus. Over 100 specialists worked on the development of the vaccine.

The mechanism of work of the vaccine is simple: it contains information about the structure of the surface viral protein in the form of information (matrix) RNA and helps to develop antibodies to this protein, providing immunity against the virus.